CytomX Therapeutics (CTMX) Earnings Date & Reports

Key Takeaways

• Total revenue was approximately $1.7 million in the third quarter of 2026, down from $6.0 million in the same period a year earlier and well below consensus estimates.
• The company reported a net loss of $0.09 per share, slightly wider than some analyst expectations of a $0.07 per share loss.
• CytomX ended the quarter with $348 million in cash, cash equivalents, and investments, including $37 million received from Regeneron for selecting two additional targets under its expanded collaboration.
• Operating expenses rose to $25.2 million from $21.7 million a year ago, driven by higher research and development (R&D) and general and administrative costs.
• Investor focus remains on the lead candidate varsetatug masetecan (Varseta-M) and CX-801 as the company advances toward a planned registrational study.
• For more context, explore the company's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Interested in automated trading ideas? Explore Trending AI Robots to see data-driven signals across the market.

Earnings Context and Why It Matters

CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company that develops conditionally activated, masked PROBODY therapeutics designed to localize treatment to the tumor microenvironment. For a company of this stage, quarterly revenue is less meaningful than cash runway, clinical execution, and partnership milestones. The third quarter 2026 report matters because it shows how the business is absorbing the conclusion of prior collaboration revenue while funding an ambitious clinical program. Investors are watching closely whether the balance sheet remains strong enough to advance Varseta-M toward a pivotal study, making the combination of declining top-line revenue and a growing cash position the central tension in this report.

Reported Results

For the third quarter ended September 30, 2026, CytomX reported total revenue of approximately $1.7 million, down from $6.0 million in the prior-year period. The decline was primarily attributed to the conclusion of the Astellas collaboration in the second quarter of 2026. Reported revenue came in well below the consensus estimate, which stood at roughly $10.4 million, and the company posted a net loss of $0.09 per share.

Total operating expenses were $25.2 million, up from $21.7 million a year earlier. Research and development expenses rose to $16.5 million from $15.3 million, driven by higher personnel-related costs and partially offset by lower Varseta-M spending due to the timing of manufacturing activities. General and administrative expenses increased to $8.7 million from $6.4 million, reflecting personnel-related expenses, consulting costs, and rent associated with the transition to a new headquarters.

On the balance sheet, the company ended the quarter with $348 million in cash, cash equivalents, and investments, up from $330 million at the end of the prior quarter. That figure included $37 million received from Regeneron after it selected two additional targets under the companies' recently expanded collaboration, underscoring the value of the company's partnership strategy even as recognized revenue declined.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking the biotech sector or seeking to surface comparable setups, exploring the AI Screener can be a useful starting point.

Market Reaction and Investor Sentiment

The market's response to the report reflected a familiar dynamic for clinical-stage biotechs: collaboration revenue is fading, but the clinical story and cash position remain the primary drivers of sentiment. The revenue miss versus consensus, combined with a slightly wider-than-expected net loss, weighed on the stock in the immediate aftermath of the release. At the same time, the strengthened balance sheet and the incremental Regeneron milestone provided a counterbalance, reminding investors that non-dilutive funding continues to flow in through partnerships. Sentiment remains cautious, with attention split between near-term financial results and the longer-term potential of the company's masked oncology pipeline.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central catalyst for CytomX is the advancement of Varseta-M, its masked antibody-drug conjugate (ADC, a targeted therapy that links an antibody to a cancer-killing drug) directed at EpCAM for metastatic colorectal cancer. Management has signaled plans to prioritize a single dose and move toward a registrational, or pivotal, study targeted for the first half of 2027. Data readouts and regulatory interactions around this program will be the most important near-term drivers.

Investors should also monitor the progress of CX-801, a masked cytokine being developed for metastatic melanoma, where initial data updates remain a key milestone. The Regeneron collaboration represents another lever, as future target selections or milestone payments could further bolster the cash position without dilution.

On the financial side, the trajectory of collaboration revenue will likely remain lumpy as legacy partnerships wind down. Expense discipline, particularly in R&D, will be critical to preserving the company's runway, which management has framed as extending into the second half of 2028. Overall, the story is increasingly defined by clinical execution rather than quarterly revenue, and investors will be watching for concrete progress toward a registrational trial.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations